Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective estrogen receptor modulators (SERMs).

T A Grese1, J A Dodge

  • 1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana 46285, USA.

Current Pharmaceutical Design
|April 10, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Self-management of the health care regimen: a comparison of nurses' and cardiac patients' perceptions.

Patient education and counseling·2011
Same author

With commentary.

Archives of disease in childhood·2010
Same author

The selective oestrogen receptor modulator, LY362321, is not neuroprotective in a rat model of transient focal ischaemia.

Journal of neuroendocrinology·2008
Same author

Cystic fibrosis mortality and survival in the UK: 1947-2003.

The European respiratory journal·2006
Same author

Shwachman-Diamond syndrome: UK perspective.

Archives of disease in childhood·2006
Same author

Cystic fibrosis is no longer an important cause of childhood death in the UK.

Archives of disease in childhood·2005
Same journal

Role of Phenolic Nanocompounds in Inflammatory Disorders: Current View and Future Aspects.

Current pharmaceutical design·2026
Same journal

Overcoming Physiological Barriers in Brain Tumor Therapy: Advances in Nanomedicine, Ultramolecular Pharmaceuticals, and Targeted Drug Delivery.

Current pharmaceutical design·2026
Same journal

Breathing Life into Research: The Transformative Potential of Lung-on-a-Chip Technology.

Current pharmaceutical design·2026
Same journal

Cross-Tissue Transcriptome-Wide Association Study Prioritizes Candidate Genes and Compound-Associated Signatures for Osteoarthritis.

Current pharmaceutical design·2026
Same journal

Emerging Role of AI in Gastroenterology and Hepatology: Revolutionizing Medical Device-Assisted Diagnosis.

Current pharmaceutical design·2026
Same journal

Nanostructured Lipid Carriers in Drug Targeting: Characterization, Patents, and Recent Innovations.

Current pharmaceutical design·2026
See all related articles

Selective Estrogen Receptor Modulators (SERMs) offer targeted effects, acting as estrogen antagonists in some tissues and agonists in others. This review highlights SERM development, focusing on structure-activity relationships and effects beyond traditional reproductive tissues.

Area of Science:

  • Endocrinology
  • Pharmacology
  • Oncology

Background:

  • Estrogens (e.g., 17 beta-estradiol) are crucial for female reproductive health and secondary sexual characteristics.
  • Estrogen's roles extend to skeletal, cardiovascular, and central nervous systems, alongside cancer risks.
  • Antiestrogens like tamoxifen exhibit tissue-specific estrogen antagonism and agonism.

Purpose of the Study:

  • To review recent advancements in Selective Estrogen Receptor Modulator (SERM) development.
  • To emphasize structure-activity relationships (SAR) of SERMs.
  • To explore SERM effects in non-traditional target tissues.

Main Methods:

  • Review of scientific literature on SERM development and function.
  • Analysis of structure-activity relationships in SERM design.

Related Experiment Videos

  • Examination of SERM efficacy in diverse physiological systems.

    • Main Results:

    • Development of SERMs like raloxifene with tissue-selective estrogen modulation.
    • Raloxifene acts as an antagonist in breast/uterus and agonist in bone/cardiovascular system.
    • SERMs demonstrate potential for targeted therapeutic applications.

    Conclusions:

    • SERMs represent a significant advancement in estrogen-related therapy.
    • Understanding SAR is key to designing more selective and effective SERMs.
    • SERMs hold promise for treating conditions in non-traditional target tissues.